{"id":"NCT02125461","sponsor":"AstraZeneca","briefTitle":"A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","officialTitle":"A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-07","primaryCompletion":"2017-02-13","completion":"2023-08-24","firstPosted":"2014-04-29","resultsPosted":"2019-01-30","lastUpdate":"2023-10-10"},"enrollment":713,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"MEDI4736","otherNames":[]},{"type":"OTHER","name":"PLACEBO","otherNames":[]}],"arms":[{"label":"MEDI4736","type":"EXPERIMENTAL"},{"label":"PLACEBO","type":"PLACEBO_COMPARATOR"}],"summary":"A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.","primaryOutcome":{"measure":"Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)","timeFrame":"Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.","effectByArm":[{"arm":"Durvalumab (MEDI4736)","deltaMin":16.8,"sd":null},{"arm":"Placebo","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":236,"countries":["United States","Australia","Belgium","Canada","Chile","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Peru","Poland","Singapore","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom","Vietnam"]},"refs":{"pmids":["36841540","35247871","35245844","35108059","34484473","34294595","33583206","33545688","33476803","33285469","32209338","31622733","31601496","30280658","28885881"],"seeAlso":["http://www.emergingmed.com/networks/AstraZeneca","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D4191C00001&amp;attachmentIdentifier=5253288a-15c6-48e2-a5b4-20315b70234e&amp;fileName=D4191C00001-CSR_synopsis_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":138,"n":475},"commonTop":["Cough","Dyspnoea","Fatigue","Diarrhoea","Arthralgia"]}}